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Article

Pleural innate response activator B cells protect
against pneumonia via a GM-CSF-IgM axis
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Pneumonia is a major cause of mortality worldwide and a serious problem in critical care
medicine, but the immunophysiological processes that confer either protection or morbidity
are not completely understood. We show that in response to lung infection, B1a B cells
migrate from the pleural space to the lung parenchyma to secrete polyreactive emergency
immunoglobulin M (IgM). The process requires innate response activator (IRA) B cells, a
transitional B1a-derived inflammatory subset which controls IgM production via autocrine
granulocyte/macrophage colony-stimulating factor (GM-CSF) signaling. The strategic
location of these cells, coupled with the capacity to produce GM-CSF–dependent IgM,
ensures effective early frontline defense against bacteria invading the lungs. The study
describes a previously unrecognized GM-CSF-IgM axis and positions IRA B cells as orchestrators of protective IgM immunity.
CORRESPONDENCE
F.K. Swirski:
fswirski@mgh.harvard.edu
OR
G.F. Weber:
georg.weber@uniklinikumdresden.de
Abbreviations used: BAL, bronchoalveolar lavage fluid; CB, cord
blood; CT, computed tomography; ICAPS, intercostal approach of the pleural space; i.n.,
intranasally; i.pls., into the pleural space; IRA, innate response
activator; i.t., intratracheal.

Respiratory infections are an acute challenge
in critical care medicine, typically affecting the
very old, very young, and chronically ill. The
Center for Disease Control and Prevention estimates that, in the United States, 1.7 million
hospital-acquired respiratory infections claim
90,000 lives every year.This mortality rate is rising
due to an increased number of immunosuppressed patients, exposure to drug-resistant organisms, and a growing elderly population (Mizgerd,
2008; Esperatti et al., 2010; Magret et al., 2011;
Venkatachalam et al., 2011).There is, therefore, an
urgent need to find novel therapeutic targets, and
to do so requires deeper understanding of the disease’s underlying pathophysiology.
Vertebrate animals rely on their diverse leukocyte populations to recognize and clear pathogens that breach mucosal barriers (Medzhitov,
2007). Infection of the lung mobilizes lymphocytes, granulocytes, and mononuclear phagocytes. Among the lymphocytes, the innate-like
B1 B cells reside predominantly in serosal cavities. In response to infection, serosal B1 B cells
relocate from either the pleural space or peritoneum and accumulate in either lung-draining
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lymph nodes or the spleen, respectively (Kawahara
et al., 2003; Ha et al., 2006; Yang et al., 2007;
Choi and Baumgarth, 2008; Moon et al., 2012).
B1 cells are major producers of natural IgM
antibodies that protect the host by opsonizing
pathogens and promoting complement receptor–
mediated phagocytosis (Boes et al., 1998;
Baumgarth et al., 2000;Ansel et al., 2002; Fabrizio
et al., 2007; Choi and Baumgarth, 2008; Racine
and Winslow, 2009; Ehrenstein and Notley,
2010; Baumgarth, 2011; Litvack et al., 2011;
Schwartz et al., 2012), but the mechanisms controlling B cell activation, as well as the consequences of relocating from serosal sites, are not
fully known. We have recently shown in an abdominal sepsis model that peritoneal B1a B
cells (a subset of B1 B cells) give rise to a population of B cells called innate response activator
(IRA) B cells that produce the growth factor
GM-CSF (Rauch et al., 2012). IRA B cells
arise in the mouse by recognizing microbes via
© 2014 Weber et al. This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months
after the publication date (see http://www.rupress.org/terms). After six months
it is available under a Creative Commons License (Attribution–Noncommercial–
Share Alike 3.0 Unported license, as described at http://creativecommons.org/
licenses/by-nc-sa/3.0/).
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Figure 1. GM-CSF controls IgM production. (A) In vitro culture of CD19+ serosal
B cells. Gating strategy and phenotyping of IRA
B cells 2 d after culture in medium or with
10 µg/ml LPS. A representative contour plot of
n > 5 is shown. (B) CD131 (Csf2rb) expression on
selected cells from WT mice (n = 4). (C) In vitro
culture of serosal B1a cells sorted from WT,
Csf2/, and Csfrb/ mice. Data show intra
cellular IgM and GM-CSF in cells cultured in
medium alone or after LPS (10 µg/ml) stimulation after 1 d of culture (n = 3–5). The gate for
GM-CSF was set using an isotype control (IgG2a)
and the gate for intracellular IgM represents the
upper 99% limit of intracellular IgM staining at
baseline. (D) In vitro culture of serosal B1a cells
sorted from WT, Csf2/, and Csfrb/ mice,
and B2 cells sorted from WT mice. Percentage
of IgM(ic)high cells cultured for 1 d in medium,
after stimulation with 10 µg/ml LPS alone, or
10 µg/ml LPS + rGM-CSF, or with a Stat5 inhibitor (n = 3–8, mean ± SD). ns, not significant.
(E) IgM ELISA of culture supernatants from the
same groups as in D (n = 3–8, mean ± SD).
ns, not significant. (F) IgM ELISPOT of cultured
B1a cells. A representative ELISPOT of n = 3 is
shown. (G) Quantitative RT-PCR analysis of Csf2
and Prdm1 expression in cultured serosal
B1a cells from WT, Csf2/, and Csf2rb/ mice
with and without LPS (10 µg/ml) stimulation for
1 d (n = 3). Csf2 expression levels after LPS
stimulation is shown relative to WT LPS as
mean ± SD. Prdm1 expression after LPS stimulation is shown relative to WT medium as
mean ± SD (nd, not detected). *, P < 0.05;
**, P < 0.01; ***, P < 0.001; ****, P < 0.0001.

TLR4 in the peritoneum and accumulate in large numbers in
the splenic red pulp.The mechanisms by which B cell–derived
GM-CSF protects against sepsis, however, are not known.
In this study, we show that in response to microbial airway
infection, pleural B1a B cells relocate to the lung where they
produce protective IgM. The process requires IRA B cells;
animals with a B cell–restricted GM-CSF deficiency fail to
secrete abundant IgM and consequently succumb to pneumonia. Mechanistically, autocrine GM-CSF activates B cells
for IgM production via the common  chain receptor CD131.
The study therefore identifies a GM-CSF-IgM activation axis
that is critical in the response to infection and reveals the
pleural space as a source of innate-like B cells that infiltrate
the lung in response to bacterial lung infection.
RESULTS
GM-CSF controls IgM production
IgM production is a defining feature of innate-like B cells
(Ehrenstein and Notley, 2010; Baumgarth, 2011; Cerutti et al.,
2013). We have previously shown that IRA B cells are B1aderived GM-CSF and IgM-producing cells (Rauch et al.,
2012), whereas others have documented that GM-CSF can
1244

induce immunoglobulin secretion (Snapper et al., 1995).
IgM and GM-CSF co-expression by the same cell prompted
us to test for a direct link between the antibody and the
growth factor. We sorted B1a B cells from serosal cavities
(peritoneal and pleural), locations known to contain B1a B cells.
After in vitro LPS stimulation, B1a B cells gave rise to GMCSF–producing IRA B cells, defined as CD19+ IgMhigh
CD43+ CD5+ CD138+ CD93+ MHCII+ (Fig. 1 A). B1a B
cells also expressed the common  chain high-affinity receptor for GM-CSF (Csf2rb, also known as CD131) at high levels (Fig. 1 B), which corresponded with transcriptional
profiling data obtained by the Immunological Genome Project (ImmGen) and suggested that B cell–derived GM-CSF
might be acting in an autocrine manner to produce IgM. To
test this, we placed sorted B1a B cells from WT, Csf2/
(i.e., GM-CSF–deficient), and Csf2rb/ mice into culture
and used flow cytometry to detect intracellular IgM reservoirs (Fig. 2, A and B). In response to LPS, WT but neither
Csf2/ nor Csf2rb/ B1a B cells gave rise to a large population of IgM-producing cells (Fig. 1, C and D). GM-CSF was
necessary but not sufficient to elicit robust IgM production
because adding GM-CSF to WT cells in medium had no
IRA B cells in pneumonia | Weber et al.
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Figure 2. Intracellular staining of IgM. (A) Serosal B1a cells
were sorted, placed in culture with LPS for 1 d, and stained for
surface and intracellular IgM. Data show that the procedure can
stain for intracellular IgM and that both surface and intracellular
staining can be resolved. Surface IgM staining is followed by
intracellular staining. A representative analysis of n > 5 is
shown. (B) Validation of IgM production by ELISPOT on sorted
B1a cavity cells 1 d after in vitro LPS stimulation. Shown is a
representative analysis from n > 5.

effect. Adding recombinant (r) GM-CSF to Csf2/ B1a
cell cultures partially restored, whereas adding rGM-CSF to
WT B1a cells augmented IgM production (Fig. 1 D). Although the rescue effect was partial in absolute values, the
10-fold increase of IgM by Csf2/ cells after rGM-CSF
was similar to that observed in WT cells. These data suggest
that despite GM-CSF’s absence during B1 cell development
in Csf2/ mice, which might affect the cells’ ability to respond to LPS, a relatively robust response nevertheless occurs,
providing evidence that GM-CSF stimulates IgM production.
To illustrate the link between GM-CSF and IgM in WT cells,
we focused on Stat5, which is crucial in the GM-CSF signaling pathway (Mui et al., 1995). Adding a Stat5 inhibitor to
B1a cell cultures abrogated IgM production. B2 cells cultured
with LPS likewise produced IgM, albeit at much lower levels.
The intracellular IgM reservoirs correlated with secreted
IgM, as measured by ELISA (Fig. 1 E) and ELISPOT (Fig. 1 F).
RT-PCR confirmed that WT and Csf2rb/ but not Csf2/
cells produced GM-CSF in response to LPS (Fig. 1 G).When
compared with Csf2/ and Csf2rb/ B1a B cells, stimulated
WT B1a B cells expressed moderately higher levels of Prdm1
(Fig. 1 H), the gene which codes for Blimp-1, which is an essential transcription factor in plasma cell generation (ShapiroShelef et al., 2003; Savitsky and Calame, 2006; Fairfax et al.,

2007; Nutt et al., 2007). In sum, the data show that B1aderived IRA B cell secretion of GM-CSF promotes IgM
production via CD131. This is a previously unrecognized GMCSF-IgM axis that may be central to the early response to
bacterial infection.
Protection against pneumonia requires pleural IRA B cells
The in vitro generation of IRA B cells from serosal B1a
B cells led us to test whether IRA B cells can arise in the airways in vivo. We delivered LPS intranasally (i.n.) to WT mice
and profiled the appearance of IRA B cells in various compartments 1 and 2 d later. Absolute IRA B cell numbers were
highest in the lung and pleural space 2 d after LPS injection,
with small numbers of IRA B cells accumulating in the bronchoalveolar lavage (BAL) and negligible numbers accumulating in both the lung-draining LN and blood at any point in
time (Fig. 3, A and B). Expressing the increase of IRA B cells
as a percentage of total B cells revealed dramatic increases in
the pleural space, lung, and BAL (Fig. 3 C).
To determine whether IRA B cells are important in the
host response to airway infection, we generated mixed chi
meric mice with a B cell–restricted GM-CSF deficiency (Fig. 4).
The procedure involved lethal irradiation of WT mice and
reconstitution with a mixture of bone marrow cells from

Figure 3. Identification of IRA B cells after airway challenge. (A) Identification of IRA B cells in the lung 2 d after LPS
i.n. challenge. A representative dot plot of n > 5 is shown.
(B) Enumeration of IRA B cells in different organs in steady-state
and after LPS challenge (n = 4/group). (C) Enumeration as percentage increase (n = 4). Relevant data are presented as mean ±
SD and tested by ANOVA; *, P < 0.05; **, P < 0.01; ***, P < 0.001.
JEM Vol. 211, No. 6
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Figure 4. Generation of mixed chimeras. (A) Leukocyte reconstitution in WT/µMT, GM/WT, and GM/µMT mice in the pleural space, blood, and lung 10 wk
after irradiation and bone marrow transfer. Data show the relative percentages of myeloid (CD11b+) and nonmyeloid (CD11b) cells in the three compartments (n = 4, mean ± SD). (B) B cells in the pleural space of a WT mouse. Gating strategy for B1a (CD19+IgMhighCD43+CD5+), B1b (CD19+IgMhighCD43+CD5),
B2 (CD19+IgMlowCD43CD5), and B reg (CD19+IgM+CD43CD5+) B cells is shown. (C) Relative proportions of total B cells and B1a B cells in the pleural space
of WT/µMT, GM/WT, and GM/µMT chimeric mice and non-irradiated WT mice in the steady state. The chimeric mice were analyzed 8 wk after bone marrow
transfer (n = 3–5, mean ± SD). (D) Enumeration of the various subsets in the three chimeras (n = 3–5, mean ± SD). (E) CD45.2 expression on blood leukocytes in
CD45.1+ mice that had been lethally irradiated and reconstituted with CD45.2+ bone marrow cells 10 wk earlier. The plot is representative from that of the three
chimeras. (F) Lung H&E in the three sets of chimeric mice 10 wk after bone marrow reconstitution (bars, 200 µm). (G) Turbidity analysis of BAL at 600 nm from
WT/µMT, GM/µMT, WTGM (lethal irradiation of WT mouse and 100% reconstitution with Csf2/ BM), and GMWT (lethal irradiation of Csf2/ mouse and 100%
reconstitution with WT BM) chimera (n = 3; mean ± SD). (H) BAL of WT/µMT, GM/WT, GM/µMT, WTGM, and GMWT chimeric mice.

µMT and GM-CSF–deficient mice. Accordingly, the µMT
bone marrow gave rise to GM-CSF–sufficient leukocytes,
but not B cells, whereas the GM-CSF–deficient bone marrow gave rise to GM-CSF–deficient leukocytes, including
B cells. After 10 wk of reconstitution, all B cells (which
necessarily derived from GM-CSF–deficient mice) lacked
the capacity to produce GM-CSF in the mixed chimeras
(GM/µMT). The remaining leukocytes were a mixture of
WT and GM-CSF–deficient cells, whereas radiation-resistant
and tissue-resident nonhematopoietic cells were GM-CSF–
sufficient. We also generated two types of controls: WT mice
reconstituted with a mixture of WT and µMT bone marrow
cells (WT/µMT), which controlled for the µMT contribution, and WT mice reconstituted with a mixture of GMCSF–deficient and WT bone marrow cells (GM/WT), which
controlled for the contribution of any GM-CSF–deficient
non–B cells in the GM/µMT group. The leukocyte profiles
1246

in the pleural space, blood, and lung in the steady-state
were most similar between the GM/µMT and WT/µMT
chimeras (Fig. 4 A), but all three chimeras developed various
B cell subsets (Baumgarth, 2011), including B1a B cells, as
expected (Düber et al., 2009; Esplin et al., 2009; Holodick
et al., 2009). Even though reconstitution was sub-optimal
compared with non-irradiated WT mice (Fig. 4, B–D), the
chimeras’ leukocytes were of donor origin (Fig. 4 E), and the
mice had normal lung histology (Fig. 4 F) without evidence of
alveolar proteinosis (Fig. 4, G and H). Complete GM-CSF
deficiency leads to the development of spontaneous alveolar
proteinosis (Dranoff et al., 1994; Stanley et al., 1994). Previous
data have shown (Huffman et al., 1996), and our data confirm, that pulmonary epithelial (i.e., nonhematopoietic)
GM-CSF–producing cells prevent proteinosis by stimulating
alveolar macrophages to clear surfactant; B cells are dispensable in this context.
IRA B cells in pneumonia | Weber et al.
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Figure 5. IRA B cells protect against pneumonia. (A) Clinical score of WT, WT receiving antiCD116, µMT, WT/µMT, GM/WT, and GM/µMT mice 9 h
after infection with E. coli (n = 5–10 mice). (B) Body
temperature of the groups above. (C) Bacterial titer in
BAL after E. coli infection of WT, WT receiving antiCD116, µMT, WT/µMT, GM/WT, and GM/µMT mice
(n = 5–10 mice). (D) Kaplan-Meier survival curves
after S. pneumoniae i.t. infection for WT/µMT, GM/WT,
and GM/µMT mice (n = 8–10). Relevant data are presented as mean ± SD and tested by ANOVA; *, P < 0.05;
**, P < 0.01; ***, P < 0.001.

After reconstitution, we infected GM/µMT, WT/µMT,
and GM/WT mice with Escherichia coli. Although E. coli are
not the predominant pneumonia-causing pathogen, they are
Gram-negative, LPS-bearing bacteria and are responsible for
a significant proportion of hospital-acquired pneumonias
(Williams et al., 2002; Klevens et al., 2007; Scott et al., 2008;
Esperatti et al., 2010; Jones, 2010; Magret et al., 2011;
Venkatachalam et al., 2011). We monitored infected mice for
morbidity and bacterial titer. As additional controls, we infected WT, B cell–deficient µMT mice (i.e., nonirradiated,
nonchimeric), and WT mice that received anti-CD116 intrapleurally (i.e., anti–GM-CSFR, the subunit of the GMCSF receptor which is specific to GM-CSF; the antibody has
been reported to be neutralizing). Three groups of mice—
µMT, WT receiving anti-CD116, and chimeric GM/µMT
(i.e., IRA KO)—became very morbid (Fig. 5 A), hypothermic
(Fig. 5 B), and had increased bacterial counts in the BAL
(Fig. 5 C). In contrast, WT mice and the two chimeric controls were more resistant to infection. The data show that
B cell–derived GM-CSF is important and beneficial to the
early response to airway infection. The similarity between
µMT and GM/µMT mice in failing to protect against infection illustrates that GM-CSF production by B cells is an essential component of the overall B cell response at this early
time point. Blocking CD116, GM-CSF’s specific receptor
subunit, confirmed that GM-CSF signaling is important in
WT mice in vivo.We also wondered whether the key finding
that IRA B cells are protective was specific to E. coli or might
also apply to other bacterial pathogens. GM/µMT mice infected with Streptococcus pneumoniae, a major cause of disease
in humans worldwide and the primary pathogen responsible
for pneumonia (Mizgerd, 2008), died earlier and in larger numbers than controls (Fig. 5 D). These data underscore the importance of IRA B cells in pneumonia, thereby prompting us
to delve further into these protective processes.
Impaired IgM production in the absence of IRA B cells
Having observed that B cell–derived GM-CSF protected
against pneumonia, we next examined the mixed chimeras’
cellular and humoral response, particularly whether the absence of B cell–derived GM-CSF associates with impaired
IgM production in vivo. In the steady-state, IgM was readily
detectable, and its similar concentrations in GM/µMT and
JEM Vol. 211, No. 6

WT/µMT mice indicated that IRA B cells are dispensable to
steady-state IgM production. After infection, control but not
GM/µMT mice showed augmented IgM in the pleural space,
lung, and serum, indicating impaired emergency IgM production in mice lacking IRA B cells (Fig. 6 A). Immunofluor
escence microscopy showed lung B cells in GM/µMT mice
to be weakly positive for IgM compared with controls (Fig. 6 B).
The data suggest that B cell–derived GM-CSF is required for
IgM production in vivo in response to lung infection.
Given GM-CSF’s reported role in emergency hematopoiesis (Zhan et al., 1998), we also tested whether the absence of
B cell–derived GM-CSF impaired the generation of monocytosis and granulopoiesis. Surprisingly, the GM/µMT chimeras
generated more, not fewer, myeloid cells. Compared with WT/
µMT controls, GM/µMT mice had higher numbers of neutrophils in the lungs, blood, and bronchoalveolar lavage (BAL)
fluid (Fig. 6, C and D). Interestingly, neutrophils in GM/µMT
mice phagocytosed bacteria poorly (Fig. 6 E), possibly reflecting insufficiency of IgM, an isotype known to facilitate complement receptor–mediated phagocytosis (Baumgarth, 2011;
Schwartz et al., 2012). Finally, GM/µMT mice expressed higher
levels of the inflammatory mediators IL-1, IL-6, TNF, and
CXCL1 in the BAL (Fig. 6 F). We did not detect IL-10 in the
groups, which argues against a B regulatory phenotype in this
model. Thus, impaired IgM production, rather than impaired
myelopoiesis, appeared to contribute to infection susceptibility
in animals lacking B cell–derived GM-CSF.
Pleural B1a B cells migrate to the lung parenchyma
Coelomate animals contain peritoneal, pleural, and pericardial cavities that shield and support internal organs. The
pleural cavity is the space between the outer parietal pleura
attached to the chest wall and the inner visceral pleura that
covers the lungs. Its primary purpose may be to aid lung function, as the pleural fluid allows the membranes to slide effortlessly during ventilation, but the space also contains immune
cells such as macrophages and B cells. Such leukocyte location
could be strategic; pleural cells may function as either sentinels against barrier-breaching or reservoirs for lung infiltration.
Our observations that serosal B1a B cells can give rise to IRA
B cells in vitro (Fig. 1 A); that IRA B cells arise in the pleural
space/lung during airway infection (Fig. 3); and that B cell–
derived GM-CSF controls IgM production in the airways
1247

(Fig. 6, A–C) prompted the hypothesis that the pleural space
sources lung-infiltrating IgM-producing B cells in response to
bacterial airway infection. To test this, we developed the
intercostal approach of the pleural space (ICAPS) method
(Fig. 7 A), in which a catheter is intercostally inserted into the
organism’s thorax at a low angle to bypass the diaphragm and
reduce the risk of puncturing the lung. When the catheter is
removed, the intercostal muscles seal the puncture canal and
prevent a pneumothorax. We confirmed the validity of this
procedure by injecting a CT imaging contrast agent into the
pleural space (Fig. 7 B) and transferring GFP+ leukocytes for
in vivo fate mapping (Fig. 7 C).
To track leukocyte migration, we transferred total pleural
and peritoneal GFP+ cells to either the pleural or peritoneal
space of mice receiving LPS. 2 d after transfer, we enumerated
GFP+ cells that had accumulated in various organs. Cells
transferred to the pleural space accumulated in the lung preferentially and were enriched for B cells (Fig. 7, D and E). In
contrast, only a small number of GFP+ cells accumulated in

the lung from the peritoneum, and only a small number of
cells accumulated in the spleen from either source (Fig. 7 E).
To focus on pleural B1a B cells specifically, we adoptively
transferred sorted pleural GFP+ B1a B cells to the pleural
space.After 2 d of LPS challenge, a substantial fraction (26%)
of all B1a cells in the lung were GFP+ (Fig. 7 F), and the
cells were readily visible by fluorescence microscopy (Fig. 7 G).
The pleural space, but not the blood, still contained many
GFP+ B1a B cells at this time point (Fig. 7 F), which suggested that pleural B1a cells relocated directly from the pleural space to the lungs. Indeed, pleural cells were readily observed
in regions close to the mesothelial layer, the single-cell barrier
known to express adhesion molecules—such as VCAM-1
(Jonjić et al., 1992)—that separates lung tissue from the pleural space.
Pleural B1a B cells produce protective IgM in the lungs
The leukocyte profile and the differences between the two delivery routes suggested that the pleural space was the preferential

Figure 6. Enhanced inflammation but attenuated IgM after E. coli airway infection in the absence of IRA B cells. (A) IgM levels detected by
ELISA in serum, BAL, and pleural space 9 h after E. coli infection (n = 6–10 mice). (B) Lung histology after E. coli infection. DAPI: blue; CD19: red; IgM:
green; merge: yellow. Representative pictographs of n = 6–10 animals/group are shown (bars: overview, 100 µm; inset, 10 µm). Arrows indicate
IgM+CD19+ cells. (C) Analysis of WT/µMT and GM/µMT mice after i.t. E. coli infection. Immunohistochemical staining for neutrophils in lung tissue and
enumeration of neutrophils measured by counts of neutrophils per field of view. A representative slide of n = 6–10 is shown (bars, 400 µm). (D) Enumeration of neutrophils in blood and BAL (n = 6–10). (E) Analysis of the phagocytic capacity of neutrophils from the BAL of WT/µMT and GM/µMT mice. Shown
are total cell numbers with phagocytosed Pkh26+ bacteria (n = 4). (F) Analysis of BAL levels for IL-1, IL-6, TNF, and CXCL1 (n = 5–15 mice). Relevant data
are presented as mean ± SD; *, P < 0.05; **, P < 0.01; ***, P < 0.001.
1248
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Figure 7. The pleural space is a reservoir of lung-infiltrating B1a B cells. (A) Cartoon depicting the ICAPS model. After skin incision, a small catheter can be navigated through the intercostal space and placed in the pleural space. (B) Preoperative: (i and ii) CT scans before insertion of the catheter.
Intraoperative: (iii and iv) CT scans immediately after insertion of the catheter. (v and vi) CT scans after injection of 300 µl Iopamidol iodine CT contrast
agent. Postoperative: (vii and viii) CT scans 10 min after the catheter was removed. There were no signs of injection into lung parenchyma, pneumotho
rax, or leakage (top row of CT scans: axial view; bottom rows of CT scans: sagittal view; arrows denote the tip of the catheter; stars donate the injected
Iopamidol iodine CT contrast agent). (C) Intrapleural (i.e., by ICAPS) transfer of GFP+ serosal cells. Cells were transferred into WT mice which were sacrificed 10 min after transfer. Data show transferred cells in the pleural space, BAL, blood, lung, bone marrow, and spleen. (D) Unsorted GFP+ serosal cells
were adoptively transferred to the pleural or peritoneal spaces of WT mice that received pulmonary LPS challenge. Data show profile of lung accumulation in recipients 2 d after transfer. A representative experiment of n = 5 is shown. (E) Enumeration of CD19+ and CD19 cells accumulating in the lung
and spleen after intrapleural or intraperitoneal transfer of unsorted GFP+ serosal cells. A representative enumeration of n = 5 is shown. (F) Intrapleural
adoptive transfer of serosal B1a GFP+ cells. Data show frequency of adoptively transferred (GFP+) cells in the lung, pleural space, and blood 2 d after pulmonary LPS challenge. A representative dot plot from n = 4 is shown. (G) Fluorescence microscopy of lung tissue 2 d after intrapleural adoptive transfer
of sorted GFP+ serosal B1a cells (bars: overview, 20 µm; inset, 10 µm).

source of lung-accumulating serosal B cells. B1a B cells retrieved from the lung contained large reservoirs of IgM (Fig. 8,
A and B), which they secreted locally, as measured by
ELISPOT assays performed on GFP+ cells that had relocated
from the pleural space to lung tissue (Fig. 8 C). To determine
JEM Vol. 211, No. 6

the importance of pleural B cells to the host response, we
profiled mortality in WT and µMT (i.e., B cell–deficient)
mice infected with a high dose of E. coli.After 48 h, 40% of WT
mice died but 60% completely recovered. In contrast, 80%
of B cell–deficient µMT mice died within 12 h (Fig. 8 D).
1249

Additionally, we used ICAPS to transfer pleural B cells from
WT mice to the pleural spaces of µMT mice.The µMT pleural B cell recipients, which now contained B cells but only
in the pleural space, were then infected with E. coli. Remarkably, this B cell supplementation completely reversed the severe mortality otherwise observed in µMT mice (Fig. 8 D).
For controls, we transferred pleural B cells from Csf2/ mice
to the pleural spaces of µMT mice and B cells sorted from the
blood of WT mice to the blood (by i.v.) of µMT mice. Neither
approach rescued the µMT mice, indicating that GM-CSF
produced by pleural B cells was required for protection. The
data show that pleural B cells defend against pneumonia.
IgM is one of the first antibody isotypes secreted during
infection. IgM recognizes multiple epitopes with low affinity
and is therefore polyreactive and innate-like, but its penta
meric structure increases avidity and allows for potent opsonizing and complement-fixing functions. To determine whether
IgM recognized bacteria in our model, we infected µMT
mice and µMT mice that received pleural B cells into the
pleural space (Fig. 8 E) with Pkh26-labeled E. coli. 6 h later,
the BAL fluid contained labeled bacteria in both groups, but
only bacteria in µMT animals receiving pleural B cells were
opsonized with IgM (Fig. 8 E). Newly produced IgM (i.e., IgM
retrieved from the BAL 6 h after LPS intratracheal [i.t.] delivery)
recognized gram-positive Staphylococcus aureus and gram-negative
Pseudomonas aeruginosa, indicating polyreactivity (Fig. 8 F).

Moreover, IgM titers were increased in the BAL and pleural
space of µMT mice receiving WT pleural B cells but not
Csf2/ pleural B cells (Fig. 8 G). These data indicate that
in response to airway infection, pleural B cells relocate to
the lung and produce opsonizing, polyreactive, GM-CSF–
dependent IgM.
Secreted IgM is necessary for protection against pneumonia
At this point, the data can be summarized as follows: in response to pulmonary infection, IRA B cells arise in the pleural space and lung; in the absence of IRA B cells (absence of
B cell–derived GM-CSF), mice fail to produce IgM and succumb to pneumonia; and pulmonary infection mobilizes
pleural B1a B cells, which relocate to the lung and produce
IgM. To further validate these findings, we wished to test the
importance of pleural B cell–derived GM-CSF and secreted
IgM in our model.We pursued a rescue strategy involving the
adoptive transfer of different cell populations to the pleural
spaces of GM/µMT mice. We transferred Csf2/ pleural
B cells,WT pleural non–B cells, pleural B cells from secretory
IgM-deficient (sIgM/) mice, and WT pleural B cells (Fig. 9 A).
Comparing the adoptive transfer of WT pleural B cells with
Csf2/ pleural B cells and WT pleural non–B cells allowed
us to determine the importance of B cell–derived GM-CSF,
whereas sIgM/ mice demonstrated the importance of secreted IgM. Mice that received WT pleural B cells into the

Figure 8. Pleural B1a B cells accumulating in the lung produce opsonizing IgM that is sufficient to confer survival. (A) Intracellular IgM (IgM
(ic)) reservoirs in steady-state pleural GFP+ B1a cells (left dot plot) and in GFP+ B1a cells that had infiltrated LPS-challenged lungs after intrapleural transfer (right dot plot). The dotted line represents the upper 99% limit of intracellular IgM staining in steady-state cells. Representative analysis from n = 4 is
shown. (B) Mean fluorescence intensity (MFI) of IgM (ic) from A (n = 4). (C) IgM ELISPOT analysis of cells as in A. Representative analysis from n = 2 experiments is shown. (D) Kaplan-Meier survival curves in response to E. coli infection in WT mice; µMT mice; and µMT mice that received WT pleural B cells
in the pleural space, Csf2/ pleural cells in the pleural space, and WT blood cells into the blood at the time of infection (n = 10 mice). (E) Opsonization of
bacteria with IgM. Data show Pkh26-labeled E. coli retrieved from the BAL of either µMT mice or µMT mice spiked with pleural WT B cells in the pleural
space. Bacteria (i.t.) and cell transfer (i.pls.) were conducted 6 h before BAL. An antibody against IgM shows opsonization of labeled bacteria. A representative analysis of n = 3 is shown. (F) IgM is polyclonal. WT mice received PBS or LPS. 6 h later, BAL was collected, and capacity of IgM to bind to S. aureus
and P. aeruginosa was measured. Data show binding relative to a commercially available polyclonal IgM (n = 3). (G) IgM ELISA of pleural fluid and BAL
after E. coli infection. µMT mice received WT or Csf2/ pleural B1a cells into the pleural space at the time of infection (n = 3). Relevant data are presented as mean ± SD; *, P < 0.05; **, P < 0.01; ***, P < 0.001.
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pleural space were healthier, as judged by their clinical scores,
body temperatures, and bacterial titers (Fig. 9 B). Moreover,
mice that received WT pleural B cells had increased titers of
IgM (Fig. 9 B). That none of the other three strategies protected the animals indicated that B cell–derived GM-CSF is
essential.To determine whether polyclonal IgM could indeed
rescue IRA B cell–deficient, GM/µMT chimeras, we injected
polyclonal IgM i.t. into GM/µMT mice infected with a high
dose of E. coli. Compared with controls receiving PBS, polyIgM recipients were protected (Fig. 9 C).
Previously, we demonstrated that the human spleen contains a population of GM-CSF–producing IRA B-like cells
(Rauch et al., 2012).To determine whether humans also contain, or can develop, IRA B-like cells in the pleural space, we
obtained human pleural fluid by thoracentesis, and cultured
B cells in either medium or a classical human B cell stimulation cocktail containing anti-Ig and IL-2. After 2 d of culture,
human pleural CD19+ CD20+ IgM+ B cells produced GMCSF (Fig. 10, A–C). The GM-CSF producers clustered in a
single rather than bimodal distribution, suggesting indiscriminate activation in this in vitro setting. To reveal whether the
appearance of IRA B-like cells was unique to the pleural
space, we also cultured B cells from cord and peripheral blood.
In the cord blood, which contains predominantly naive and
transitional cells, a large GM-CSF–producing population
likewise arose (Fig. 10 C). In contrast, culturing peripheral
blood B cell did not stimulate GM-CSF production (Fig. 10 C),
a result which supports the concept that IRA B cells arise in
specific locations. Adding nontoxic doses of anti–GM-CSF,
anti-CD116, or a STAT5 inhibitor to the culture containing
pleural cells prevented the appearance of IRA B-like cells,
further indicating an important role of the GM-CSF pathway

(Fig. 10 D). Although further work is required to elucidate
the similarities and differences between murine and human IRA
B cells, these data nevertheless illustrate our current findings’
potential translatability. In sum, the production of GM-CSF by
IRA B cells orchestrates the generation of protective IgM, which
is critical in the early defense to infection (Fig. 10 E).
DISCUSSION
The innate immune mechanism described here clears bacteria
and protects against pneumonia. We show that in response
to infection, pleural B cells relocate to the lung and produce
abundant natural IgM, which is known to protect against infection (Boes et al., 1998; Baumgarth et al., 2000; Fabrizio
et al., 2007; Choi and Baumgarth, 2008; Litvack et al., 2011;
Schwartz et al., 2012). B cell–derived GM-CSF is the autocrine instructor required for emergency IgM production.
Recently identified IRA B cells, which differentiate from B1a
B cells in the mouse via direct TLR-dependent pathogen recognition, are key to this process and therefore to early innate
immune defense.
GM-CSF was identified in the 1960s as a colony stimulator
of granulocytes and mononuclear cells, though not erythrocytes
(Bradley and Metcalf, 1966). GM-CSF–deficient mice, which
were independently generated by two groups in 1994 (Dranoff
et al., 1994; Stanley et al., 1994), show no striking perturbations of hematopoiesis in the steady state but develop alveolar
proteinosis. This condition’s human counterpart is characterized by elevated anti–GM-CSF autoantibodies (Carey and
Trapnell, 2010). In the mouse, GM-CSF is produced by
pulmonary epithelial cells (Huffman et al., 1996), T cells, and
macrophages (Hamilton, 2008; Hamilton and Achuthan,
2013). The growth factor promotes the maturation, survival,

Figure 9. IRA B cells and secreted IgM are required for protection against pneumonia. (A) Postsort analysis of sorted WT, sIgM/, Csf2/
serosal B cells, or WT serosal non–B cells. Representative plots are shown of n > 10. (B) GM/µMT (i.e., IRA B cell KO) mice received intrapleural transfer of
WT, sIgM/, Csf2/ serosal B cells, and WT non–B cells (n = 6–15 mice). 6 h later, mice were infected i.t. with E. coli. 9 h later, clinical score, body temperature, bacterial titer in the BAL, and IgM in serum were measured. Data are presented as mean ± SD and tested by ANOVA. (C) Kaplan-Meier Survival
Curve of GM/µMT mice infected with E. coli receiving either PBS or polyclonal IgM i.t. (n = 10). Relevant data are presented as mean ± SD; ***, P < 0.001.
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Figure 10. IRA B cells in humans. (A) Human pleural B cells were
placed in vitro for 2 d and stimulated with anti-Ig and IL-2. Data show
the appearance of GM-CSF–producing, IRA-like B cells. (B) Fluorescenceminus-one (FMO) and isotype controls of stimulated human B cells.
(C) Total B cells were collected from human pleural space, cord blood, and
peripheral blood and cultured for 2 d either in medium or with anti-Ig
and IL-2 stimulation. Data show quantity of IRA-like B cells appearing in
each condition. (D) Total B cells from the pleural space were cultured as in C,
and with anti–GM-CSF, anti-CD116, or a Stat5 inhibitor. Data show
quantity of IRA-like B cells appearing in each condition (n = 4–15). Relevant data are presented as mean ± SD. ***, P < 0.001. (E) Model for the
function of IRA B cells in mouse pneumonia. During airway infection
pleural space B1a cells recognize bacteria or its components (1). This leads
to the generation (2) of IRA B cells which produce GM-CSF and express
the GM-CSF receptor. GM-CSF acts on its receptor in an autocrine (3)
manner. The signaling orchestrates generation of IgM-producing cells (4)
which relocate to the lung (5). IgM derived from pleural space B cells is
essential to the control of bacteremia (6).
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and proliferation of its target cells; it controls nonlymphoid
tissue dendritic cell homeostasis (Greter et al., 2012), emergency granulopoiesis (Kimura et al., 2009), iNKT cell differentiation (Bezbradica et al., 2006), sensitization to allergen
(Stämpfli et al., 1998), and other effects related to immune activation (Hege et al., 2006; Timmerman et al., 2009; Le et al.,
2010). In vitro, GM-CSF remains a standard for differentiating bone marrow progenitors to dendritic cells.
The early appearance of a unique GM-CSF–producing
B cell in sepsis suggests a leukocyte communication hierarchy
in which IRA B cells educate their client myeloid cells. A major
finding of this study is therefore unexpected: IRA B cells produce GM-CSF for themselves. This autocrine function is all
the more surprising considering its outcome, which is IgM
production. At the signaling level, this may involve Blimp-1,
a transcriptional repressor required for the formation of
immunoglobulin-secreting B1-derived plasma cells (ShapiroShelef et al., 2003; Savitsky and Calame, 2006; Fairfax et al.,
2007; Nutt et al., 2007) and Stat5, a transcription factor
downstream of GM-CSF signaling (Mui et al., 1995; Kimura
et al., 2009) which has been recently shown to amplify Blimp-1
in T cells (Nurieva et al., 2012). Future studies will need to
elucidate the precise sequence of events that link GM-CSF
signaling to IgM production. In addition to investigating how
signals downstream of GM-CSF and LPS integrate, activate
Stat5 and Blimp-1, and cooperate to produce IgM, additional
questions remain as to whether and how GM-CSF contributes to the generation of mature B1 cells. Because pleural
B cells can also accumulate in the lung-draining lymph nodes
(Choi and Baumgarth, 2008), future work must determine
whether IRA B cell–derived GM-CSF elicits other responses,
such as generating or activating dendritic cells.
Many cytokines have an endocrine function. IL-1, IL-6,
and TNF, for example, travel in the bloodstream and affect
tissues at distance from injury or infection. Evidence suggests that GM-CSF’s activity is more spatially restricted. Serum
levels of GM-CSF tend to be low in steady state and inflammation because of receptor and autoantibody-mediated clearance (Metcalf et al., 1999). GM-CSF’s pleiotropy relies on
a binary, concentration-dependent switch (Guthridge et al.,
2006). In this study, we show that B cell–derived GM-CSF
is necessary for protective IgM responses but dispensable to
surfactant clearance by alveolar macrophages. The cellular
source and location of GM-CSF, our data indicate, is important and may be particularly relevant during clinical intervention. Indeed, on the basis of GM-CSF’s capacity to augment
HLA-DR and potentially arm the host for effective immunity,
clinical trials have explored using recombinant GM-CSF
for sepsis treatment (LaRosa and Opal, 2012). A few studies
showed an all-survival benefit, but a meta-analysis found no
consensus among the trials, and thus no evidence to support
routine GM-CSF use (Bo et al., 2011). In all trials, however,
GM-CSF was delivered either intravenously or subcutaneously. Future studies will need to determine whether locally
administering GM-CSF to strategic locations, such as the
IRA B cells in pneumonia | Weber et al.
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pleural space, can overcome host clearance mechanisms and
engender a durable clinical benefit.
The adaptive arm of the immune system requires lymphoid
tissues in which leukocytes interact, proliferate, and, over time,
generate antigen specificity and memory. For innate immunity
to be effective, it must respond to a different challenge: it has
to act quickly. The pleural space’s proximity to the lung gives
pleural leukocytes an advantage in meeting this challenge. The
observation that pleural space B cells control the early response
to infection is significant because it broadens our understanding of the immune system’s spatio-cellular dynamics. Additionally, the mechanistic insight that a particular B cell controls this
event via a previously unrecognized GM-CSF-IgM axis might
have important biological and therapeutic implications for the
treatment of infectious diseases.
MATERIALS AND METHODS
Animals
C57BL/6J (WT), B6.SJL-PtprcaPepcb/BoyJ (CD45.1+), C57BL/6-Tg(UBCGFP)30Scha/J (GFP+), and B10.129S2(B6)-Ighmtm1Cgn/J (MT) female
mice (The Jackson Laboratory) were used in this study. GM-CSF–deficient
mice (Csf2/) were a gift from R. Seeley (University of Cincinnati, Cincinnati, OH). Secretory IgM-deficient mice (sIgM/) were a gift from
K. Alugupalli (Thomas Jefferson University, Philadelphia, PA). GM-CSF
receptor-deficient mice (Csf2rb/) were a gift from J. Whitsett (Cincinnati
Children’s Hospital Medical Center, Cincinnati, OH). All mice were 8–20 wk
of age at the time of sacrifice. All protocols were approved by the Animal Review Committee at Massachusetts General Hospital.

Animal models and in vivo interventions
For the adoptive transfer of cells i.v., i.p., or into the pleural space (i.pls.),
mice were anesthetized with isoflurane.
Intrapleural injection using the ICAPS model. After fixation of the
mice with tape, a right anterolateral thoracic incision was performed over
2–3 cm, followed by careful sharp dissection of the attached muscles from the
thoracic wall. A polyethylene catheter (Intramedic, I.D. 0.28 mm; BD) was
then tangentially inserted into the pleural space without harming the lung
parenchyma. Cells, contrast agent, or PBS was injected. After removing the
catheter, we controlled for pneumothorax and adequate breathing. Skin
closure was performed with an Ethilon 5/0 suture and pain medication
(0.1 mg/kg buprenorphine) was injected i.p.
Mixed bone marrow chimeras. Naive WT mice were lethally irradiated
(10 Gy). 4–7 h after irradiation, animals were reconstituted with a 1:1 mixture of total bone marrow cells from MT, WT, or Csf2/ mice (Rauch
et al., 2012). A total of 4 × 106 cells were injected intravenously. Animals
were allowed to recover for a minimum of 8 wk.
Pneumonia models. Animals were infected i.n. or i.t. with 20 µg LPS; 2.5, 5,
7.5, or 15 × 106 CFU E. coli (American Type Culture Collection); or 2.5 × 104
S. pneumoniae (American Type Culture Collection) in a volume of 50 µl saline.
Survival. Animals injected i.t. with high doses of bacteria were monitored
for survival over the course of 10 d.
Clinical score. The clinical score of each animal was assessed blinded as follows (points in parentheses). [a] appearance: normal (0), lack of grooming (1),
piloerection (2), hunched up (3), above and eyes half closed (4); [b] behavior unprovoked: normal (0), minor changes (1), less mobile and isolated (2),
restless or very still (3); behavior - provoked: responsive and alert (0), unresponsive and not alert (3); [c] clinical signs: normal respiratory rate (0), slight
changes (1), decreased rate with abdominal breathing (2), marked abdominal
JEM Vol. 211, No. 6

breathing and cyanosis (3); [d] hydration status: normal (0), dehydrated (5).
The higher the score is, the worse the clinical situation of the animal.
Temperature. The body temperature of each animal was measured by rectal insertion of a temperature sensor while the mouse was under anesthesia.
CD116 (GM-CSF-Ra) antibody injection. 200 µg anti–GM-CSF-R
(anti-CD116; R&D Systems) was i.pls. injected 2 h before infection with E. coli.
Polyclonal IgM injection. 25 µg in 50 µl polyclonal IgM (Rockland) was
injected i.t. 3 h after E. coli infection.
Cell injection. Sorted cells, as defined below and in figures, were injected
i.pls., i.p., and i.v. at time points defined in figures.

Bacteria
Bacterial titer. Bronchoalveolar lavage (BAL) samples were diluted, plated
on tryptic soy agar (BD), and incubated at 37°C. The number of bacterial
colonies was assessed 12–14 h later.
Detection of bacterial IgM coating after Pkh26 labeling. E. coli
were labeled with Pkh26 (Sigma-Aldrich) according to the manufacturer’s
instructions. After i.t. infection with 5 × 106 CFU labeled E. coli, bacteria
in the BAL were stained with anti–IgM-APC and anti–CD45.2–Pacific
blue. For FACS analysis, the flow cytometric FSC and SSC setting was set
to detect bacteria.
Phagocytosis assay. Phagocytosis was assessed using a pHrodo E. coli BioParticles Phagocytosis kit (Invitrogen) as instructed by the manufacturer.
Polyclonality assay. High protein binding capacity microtiter plate wells
(Nunc Maxisorp; Sigma-Aldrich) were coated overnight at 4°C with 107
CFU of S. aureus or P. aeruginosa. After washing, a 1% BSA blocking solution
was added to each well for 4 h at room temperature. Wells were washed and
200 µl BAL obtained 6 h after challenging WT mice with either PBS or LPS
(E. Coli O55:B5; Sigma-Aldrich) was added to each well for 4 h at room
temperature. After washing, 200 µl polyclonal anti–IgM–Alexa Fluor 488
antibodies (Abcam) diluted to 1:200 were added for 1 h at room temperature
in the dark. Fluorescence was read on a Spectramax M3 plate reader (Molecular
Devices). Mouse polyclonal IgM (Rockland) diluted to 1:1,000 served as a
positive control for IgM.

Murine leukocytes
Isolation. Peripheral blood for flow cytometry was collected by aortic puncture, using a 50 mM EDTA solution as anticoagulant. Erythrocytes were lysed
using RBC Lysis Buffer (BioLegend). Total white blood cell count was obtained by preparing a 1:10 dilution of (undiluted) peripheral blood from the
orbital sinus using heparin-coated capillary tubes in RBC Lysis Buffer (BioLegend). After organ harvest, single cell suspensions were obtained as follows:
for bone marrow, the femur and tibia of one leg were flushed with PBS through
a 40-µm nylon mesh. Spleens and lymph nodes were homogenized through a
40-µm nylon mesh, after which erythrocyte lysis was performed using RBC
Lysis Buffer (BioLegend). Lungs and liver were cut into small pieces and subjected to enzymatic digestion with 450 U/ml collagenase I, 125 U/ml collagenase XI, 60 U/ml DNase I, and 60 U/ml hyaluronidase (Sigma-Aldrich) for
1 h at 37°C while shaking. Total viable cell numbers were obtained using Trypan Blue (Cellgro; Corning). For selected experiments, the pleural space was
lavaged with 2 × 1 ml PBS and the peritoneal space was lavaged with 2 × 5 ml
of PBS to retrieve leukocytes. BAL was performed by flushing the lungs with
4 × 1 ml PBS to retrieve the infiltrated and resident leukocytes. Single-cell
suspensions were prepared or cells were MACS-sorted according to the manufacturer’s instructions and as described below.
In vitro culture. Cells were cultured in 96-well round-bottom plates
(Corning) and kept in a humidified CO2 incubator at 37°C for 24 h. B1a
cells were cultured in RPMI-1640 supplemented with 10% fetal bovine
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serum, 25 mM Hepes, 2 mM l-glutamine, 100 U/ml penicillin, 100 U/ml
streptomycin, and 50 µM -mercaptoethanol. All cell types were seeded at a
density of 30,000 cells/100 µl medium. Where indicated, LPS was added at
10 µg/ml. Stimulation of the cells was performed by adding 0.2 µg/ml rGMCSF in PBS. The Stat5 inhibitor (CAS 285986–31-4; Santa Cruz Biotechnology, Inc.) was used at 50 µg/ml (i.e., 200 nM).

Human leukocytes
Isolation. As part of a collaboration with the Feinstein Institute, cells were
separately obtained from fresh peripheral blood samples of human adult
healthy donors according to IRB-approved protocols (North Shore-LIJ
Health System), and from fresh umbilical cord blood of anonymous donors
provided by the Tissue Donation Program at the Feinstein Institute for Medical
Research. Mononuclear cells from both adult peripheral (PBL) and umbilical
cord (CB) blood were obtained by density gradient separation using lymphocyte separation medium (Cellgro). Cells were also obtained from fresh fluid
of patients undergoing paracentesis or thoracentesis at Massachusetts General
Hospital who required the procedure for diverse conditions, most frequently
cancer. The samples were de-identified for the purposes of this study. The
centesis involved sterile prepping of the skin and subcutaneous anesthesia of
tissue with Lidocaine. A small 7 Fr thoracentesis catheter was placed in the
fluid containing space, allowing removal of the fluid.
In vitro culture. Mononuclear cells (105/200 µl) were plated in medium alone
(RPMI, 10% fetal calf serum, 2 mM l-glutamine, 10 mM Hepes, 100 U/ml
penicillin, 100 µg/ml streptomycin, 1 mM sodium pyruvate, and 1× nonessential amino acids [Life Technologies]), or in medium with 2.5 µg/ml
goat anti–human IgA + IgG + IgM (Jackson ImmunoResearch Laboratories,
Inc.) and 10 ng/ml IL-2 (PeproTech) in 96-well U-bottom plates. Blocking
antibodies were added at 10 µg/ml and STAT5 inhibitor at 50 µg/ml. Cells
were cultured at 37°C, 5% CO2 for 2 d. 3 h before harvesting, 0.2 µl Golgi
Plug (BD) was added to the cultured cells to inhibit intracellular protein
transportation. Cultured cells were then harvested and immunofluorescently
stained for flow cytometric analysis (see below).

Flow cytometry
The following antibodies were used for flow cytometric analyses. Mouse: anti–
CD43-FITC, S7 (BD); anti–Ly6C-FITC, AL-21 (BD); anti–IgM-FITC, II/41
(BD); anti–CD3e-FITC, 145-2C11 (BD); anti–B220-PE, RA3-6B2 (BD);
anti–CD19-PE, 1D3 (BD); anti–NK1.1-PE, PK136 (BD); anti–CD49b-PE,
DX5 (BD); anti–90.2-PE, 53–2.1 (BD); anti–Ly6G-PE, 1A8 (BD); anti–
Ter119-PE, TER-119 (BD); anti–CD43-PE, S7 (BD); anti–GM-CSF-PE,
MP1-22E9 (BD); anti–CD131-PE, JORO50 (BD); anti–IgG2A-PE, RTK2758
(BD); anti–IgG1-PE, A85-1 (BD), anti–IgM-PerCPCy5.5, R6-60.2 (BD);
anti–MHCII-PerCPCy5.5, AF6-120.1 (BioLegend); anti–CD11c-PerCPCy5.5, HL3 (BD); anti–CD8-PerCPCy5.5, 53–6.7 (BD); anti–IgG2APerCP, RTK2758 (BD); anti–CD5-PECy7, 53–7.3 (eBioscience);
anti–CD90.2-PECy7, 53–2.1 (BD); anti–CD45.1-PECy7, A20 (BD); anti–
F4/80-PECy7, BM8 (BioLegend); anti–IgM-APC, II/41 (BD); anti–CD43APC, S7 (BD); anti–BrdU-APC (BD); anti–Ly6C-APC, AL-21 (BD);
anti–CD25-APC, PC61 (BD); anti–CD138-biotin, 281–2 (BD); anti–MHCII–
Alexa Fluor 700, M5/114.15.2 (eBioscience); anti–CD4-Alexa Fluor 700,
GK1.5 (eBioscience); anti–CD19-APCCy7, 6D5 (BioLegend); anti–CD11bAPCCy7, M1/70 (BD); anti–IgM-APCCy7, RMM-1 (BioLegend); anti–
CD45.2–Pacific blue (BD); anti–CD19-Brilliant Violet 421, 6D5 (BioLegend);
anti–IgM-BrilliantViolet 421, RMM-1 (BioLegend); anti–CD11b-BrilliantViolet 421, M1/70 (BioLegend); and anti-CD93, AA4.1-FITC (BD). Streptavidin–
Alexa Fluor 700 (Invitrogen) was used to label biotinylated antibodies. B cell
populations were identified as described previously (Rauch et al., 2012).
Human: anti–CD19-APC-A700, J3-119 (Beckman Coulter); anti–GM-CSFPE, BVD2-21C11 (BD); anti–CD20-PE-Cy7, L27 (BD); anti–IgM-PacBlue,
G20-127 (BD); anti–GM-CSF (blocking), 3209 (R&D Systems); anti–GMCSFR (blocking; CD116), K2B7.17A (Millipore); Aqua Live/Dead Stain
(Life Technologies), rat IgG2a-isotype-PE (BD).
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Intracytoplasmatic staining of IgM. Isolated cells were stained for
30 min with a primary IgM antibody (i.e., APC channel) in a high concentration (1:200) to ensure saturation of surface IgM together with additional
surface antibodies in normal concentration (1:700). After cell membrane
permeabilization using the Cytofix/Cytoperm Plus kit (BD), intracytoplasmatic IgM was performed using the secondary IgM antibody (i.e., PerCP
channel) in a lower concentration (1:350). Data were acquired on either
LSRII (BD) or Gallios (Beckman Coulter) flow cytometers and analyzed
with FlowJo (v8.8.6/v9.7.2; Tree Star). Cells were sorted on a FACSAria II
(BD) cell sorter.

Histology and imaging
Preparation. The lungs were filled with a mixture of O.C.T. compound
(Sakura) and PBS (1:1) through trachea before harvesting and embedding in a
2-methylbutane bath (Sigma-Aldrich) on dry ice. Serial 6-µm fresh-frozen
sections were prepared and stored at 80°C until immunohistochemical staining was performed. Lungs from WT/µMT, GM/WT, and GM/MT mice
were stained with hematoxylin and eosin for overall histological analysis.
Immunohistochemistry. Frozen lung sections were briefly treated with
0.3% hydrogen peroxidase solution for endogenous peroxidase inactivation.
The sections were incubated with a neutrophil antibody (NIMP-R14; Santa
Cruz Biotechnology, Inc.) for 1 h at room temperature, followed by a bio
tinylated secondary antibody (Vector Laboratories) and an avidin-biotin complex (ABC) kit (Vector Laboratories). AEC (3-amino-9-ethylcarbazole)
substrate (Dako), which forms a red end-product, was used for the color development. All sections were counterstained with Harris hematoxylin solution (Sigma-Aldrich) and coverslipped using an aqueous mounting medium.
All the histological images were captured using a digital slide scanner (NanoZoomer 2.0RS; Hamamatsu).
Immunofluorescence microscopy. The lung sections were incubated
with anti-CD19, 1D3 (BD), overnight at 4°C and Alexa Fluor 594 goat anti–
rat IgG (Invitrogen), followed by anti–IgM-FITC, II/41 (BD). The slides
were coverslipped using a mounting medium with DAPI (Vector Laboratories) to identify the nuclei. Images were captured and processed using an epifluorescence microscope (Eclipse 80i; Nikon Instruments Inc.).
Computed tomography (CT). Mice were imaged with CT using an Inveon small animal scanner (Siemens). CT images were reconstructed from
360 cone-beam x-ray projections with a power of 80 keV and 500 A. The
isotropic resolution of the CT images was 60 µm. Before CT acquisition,
iodine contrast was infused into the pleural space.The CT acquisition time was
10 min. Reconstruction of datasets was done using IRW software (Siemens).
Three-dimensional visualizations were produced using the DICOM viewer
OsiriX (The OsiriX foundation).

Molecular Biology
ELISA. Human and mouse IgM was measured with an ELISA kit according
to the manufacturer’s instructions (Bethyl Laboratories, Inc.).
Luminex. Cytokines and chemokines in the bronchoalveolar lavage,
the pleural space lavage, and serum were measured using a Luminex panel
from Invitrogen.
ELISPOT. Cells were seeded at a density of 1,000–5,000 cells/100 µl medium.
The assay (Mabtech) was performed according to the manufacturer’s instructions.
RT-PCR. Total RNA was isolated from 3–10 × 104 FACS-sorted cells
using the RNeasy Micro kit (QIAGEN) according to the manufacturer’s instructions. cDNA was generated using the iScript Select cDNA Synthesis kit
(Bio-Rad Laboratories). Real-time PCR was performed in duplicates using
the TaqMan Gene Expression Assay System on a 7300 Real-Time PCR Sys
tem (Applied Biosystems). Primers for GM-CSF (Csf2; Mm01290062_m1),
Blimp1 (Prdm1; Mm00476128_m1), and housekeeping gene -actin
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(4352341E) were used (Applied Biosystems). Relative gene expression levels
were calculated with the 2ct method.

Statistics
Results were expressed as mean ± SD. Statistical tests included unpaired, twotailed Student’s t test using Welch’s correction for unequal variances and oneway ANOVA, followed by Tukey’s or Newman-Keuls Multiple Comparison
Test. P-values of 0.05 or less were considered to denote significance.
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